Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Atai的DMt抗抑郁药物显示出潜力，准备进入第二阶段临床试验并与大型制药公司合作。
Atai Life Sciences (NASDAQ:ATAI) announced promising preliminary results on Tuesday for its DMT-based depression therapy, VLS-01. As BioSpace reported, these findings from a Phase Ib study position Atai to move forward with a Phase II trial later this year, targeting patients with treatment-resistant depression.
Atai Life Sciences (NASDAQ: ATAI)在周二发布了其基于DMt治疗抑郁症的VLS-01的令人期待的初步结果。正如BioSpace报道的那样，这些来自一项Phase Ib研究的发现使Atai有望于今年晚些时候进行第二期试验，针对的是患有难治性抑郁症的患者。
Promising Phase Ib Results For DMT-Based Depression Therapy
基于DMt治疗抑郁症的相 Phase Ib 的有望结果
VLS-01, an oral formulation of N,N-dimethyltryptamine (DMT), is designed to be administered via a buccal film applied to the lining of the cheek. This delivery method aims to induce a short, controlled psychedelic experience, potentially offering relief to those suffering from treatment...
VLS-01 是一种口服N，N-二甲基色胺（DMT）制剂，旨在通过贴在口腔内侧的颊膜片形...
登录免费看全文
登录/注册